Zurcher Kantonalbank Zurich Cantonalbank Reduces Holdings in Kenvue Inc. (NYSE:KVUE)

Zurcher Kantonalbank Zurich Cantonalbank lowered its position in shares of Kenvue Inc. (NYSE:KVUE) by 22.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 369,808 shares of the company’s stock after selling 107,919 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Kenvue were worth $7,895,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in KVUE. Grove Bank & Trust increased its stake in Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after purchasing an additional 947 shares during the last quarter. Geneos Wealth Management Inc. acquired a new stake in Kenvue in the fourth quarter worth about $29,000. SRS Capital Advisors Inc. lifted its holdings in Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock worth $30,000 after purchasing an additional 571 shares during the period. Fortitude Family Office LLC lifted its holdings in Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after purchasing an additional 777 shares during the period. Finally, Ashton Thomas Securities LLC acquired a new stake in Kenvue in the 3rd quarter valued at about $35,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Trading Up 0.5 %

Shares of Kenvue stock opened at $23.20 on Friday. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The stock has a market cap of $44.33 billion, a P/E ratio of 43.76, a P/E/G ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The business’s 50 day moving average is $21.81 and its 200-day moving average is $22.37.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were given a dividend of $0.205 per share. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.54%. Kenvue’s dividend payout ratio is currently 154.72%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Citigroup cut their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. Barclays dropped their target price on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a report on Friday, January 17th. Piper Sandler boosted their price target on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research note on Monday, February 24th. UBS Group decreased their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Finally, Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and decreased their target price for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, Kenvue currently has an average rating of “Hold” and a consensus price target of $23.75.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.